ICL Israel Chemicals (ICL) financial statements
ICL Israel Chemicals reported revenue of $7.2B in fiscal 2025, up 3.3% a year over 9 years.
Net income was $226M and the operating margin 8.1%, against -0.1% in 2016.
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from ICL Israel Chemicals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4B | $5.4B | $5.6B | $5.3B | $5.0B | $7.0B | $10.0B | $7.5B | $6.8B | $7.2B |
| Cost of revenue | $3.7B | $3.7B | $3.7B | $3.5B | $3.6B | $4.3B | $5.0B | $4.9B | $4.6B | $5.0B |
| Gross profit | $1.7B | $1.7B | $1.9B | $1.8B | $1.5B | $2.6B | $5.0B | $2.7B | $2.3B | $2.2B |
| Research and development | $73M | $55M | $55M | $50M | $54M | $64M | $68M | $71M | $69M | $70M |
| Selling, general and admin | $321M | $261M | $257M | $254M | $232M | $276M | $291M | $260M | $259M | $299M |
| Operating income | -$3M | $629M | $1.5B | $756M | $202M | $1.2B | $3.5B | $1.1B | $775M | $580M |
| Interest expense | $112M | $111M | -$103M | -$115M | $109M | $112M | $113M | $125M | $122M | $117M |
| Pre-tax income | -$117M | $505M | $1.4B | $628M | $49M | $1.1B | $3.4B | $974M | $636M | $441M |
| Income tax | $55M | $158M | $129M | $147M | $25M | $260M | $1.2B | $287M | $172M | $161M |
| Net income | -$122M | $364M | $1.2B | $475M | $11M | $783M | $2.2B | $647M | $407M | $226M |
| EPS (diluted) | -$0.10 | $0.29 | $0.97 | $0.37 | $0.01 | $0.60 | $1.67 | $0.50 | $0.32 | $0.18 |
| Diluted shares | 1.27B | 1.28B | 1.28B | 1.28B | 1.28B | 1.29B | 1.29B | 1.29B | 1.29B | 1.29B |
| Gross margin | 31.0% | 30.9% | 33.4% | 34.5% | 29.5% | 37.5% | 50.2% | 35.4% | 33.0% | 30.6% |
| Operating margin | -0.1% | 11.6% | 27.3% | 14.3% | 4.0% | 17.4% | 35.1% | 15.1% | 11.3% | 8.1% |
| Net margin | -2.3% | 6.7% | 22.3% | 9.0% | 0.2% | 11.3% | 21.6% | 8.6% | 5.9% | 3.2% |
Balance sheet
Fiscal years, from ICL Israel Chemicals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $87M | $83M | $121M | $95M | $214M | $473M | $417M | $420M | $327M | $291M |
| Receivables | $966M | $932M | $990M | $778M | $883M | $1.4B | $1.6B | $1.4B | $1.3B | $1.4B |
| Inventory | $1.3B | $1.2B | $1.3B | $1.3B | $1.2B | $1.6B | $2.1B | $1.7B | $1.6B | $1.9B |
| Total current assets | $2.6B | $2.7B | $2.8B | $2.7B | $2.8B | $3.9B | $4.5B | $4.0B | $3.6B | $4.2B |
| Property, plant and equipment | $4.3B | $4.5B | $4.7B | $5.3B | $5.5B | $5.8B | $6.0B | $6.3B | $6.5B | $6.8B |
| Total assets | $8.6B | $8.7B | $8.8B | $9.2B | $9.7B | $11.1B | $11.8B | $11.6B | $11.3B | $12.4B |
| Total current liabilities | $2.0B | $2.3B | $2.0B | $1.8B | $2.2B | $2.6B | $2.6B | $2.6B | $2.3B | $3.1B |
| Long-term debt | $2.8B | $2.4B | $1.8B | $2.2B | $2.1B | $2.4B | $2.3B | $1.8B | $1.9B | $1.9B |
| Total liabilities | $5.9B | $5.8B | $4.9B | $5.1B | $5.6B | $6.3B | $6.0B | $5.6B | $5.3B | $6.2B |
| Shareholders' equity | $2.6B | $2.9B | $3.8B | $3.9B | $3.9B | $4.5B | $5.5B | $5.8B | $5.7B | $6.0B |
| Net debt | $3.3B | $3.1B | $2.3B | $2.5B | $2.2B | $2.2B | $2.1B | $2.0B | $1.7B | $2.0B |
Cash flow
Fiscal years, from ICL Israel Chemicals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $966M | $847M | $620M | $992M | $804M | $1.1B | $2.1B | $1.7B | $1.5B | $1.1B |
| Stock-based compensation | $15M | $16M | $19M | $12M | — | — | — | — | — | — |
| Dividends paid | $162M | $237M | $241M | $273M | $118M | $276M | $1.2B | $474M | $251M | $224M |
| Net borrowing | -$87M | -$421M | -$369M | -$32M | $42M | $110M | -$136M | -$203M | -$413M | $67M |
| Dividends per share | $0.13 | $0.19 | $0.19 | $0.21 | $0.09 | $0.21 | $0.90 | $0.37 | $0.19 | $0.17 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ICL.
Open ICL in InvestinglyQuestions
What was ICL Israel Chemicals's revenue in 2025?
$7.2B in fiscal 2025, from its 10-K filing.
From ICL Israel Chemicals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.